Mediwound (MDWD)
NASDAQ:MDWD
Want to see MDWD full AI Analyst Report?
Top Page
Mediwound
(NASDAQ:MDWD)
Select Model
Select Model
Rating:43Neutral
Price Target:
$14.00
▼(-14.63% Downside)
Action:Reiterated
Date:05/28/26
MDWD scores low primarily due to weak financial performance (declining TTM revenue, very large losses, and significant cash burn). Technicals also weigh on the score with a sustained downtrend despite oversold readings. The earnings call adds some support via reaffirmed guidance and strong government-backed opportunities, but near-term execution and cash usage remain key risks; valuation is difficult to justify with negative earnings and no dividend yield provided.
Positive Factors
Government contract (BARDA)
A decade‑long BARDA contract provides a durable, government‑backed revenue stream, supporting predictable procurement and stockpile buys. This reduces reliance on volatile commercial demand, underpins scale-up economics, and improves visibility for multi-year manufacturing and development planning.
Negative Factors
Sustained cash burn
Meaningful negative operating and free cash flow signal ongoing reliance on external financing to fund R&D and operations. Continued high burn reduces runway, raises dilution risk if capital markets tighten, and constrains strategic optionality for commercialization or M&A over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Government contract (BARDA)
A decade‑long BARDA contract provides a durable, government‑backed revenue stream, supporting predictable procurement and stockpile buys. This reduces reliance on volatile commercial demand, underpins scale-up economics, and improves visibility for multi-year manufacturing and development planning.
Read all positive factors
Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$182.67M
Dividend YieldN/A
Average Volume (3M)83.89K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-24.64%
EPS Growth-8.25%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.26
Shares Outstanding12,845,664
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue8.23
Enterprise Value/Gross Profit41.97
Enterprise Value/Ebitda-8.03
Forecast
1Y Price Target
$29.00Price Target Upside76.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$24.20M
Mediwound Business Overview & Revenue Model
Company Description
MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key comme...
How the Company Makes Money
MediWound makes money primarily by commercializing its approved product NexoBrid and by partnering with third parties for distribution and market access. Revenue is generated from product sales (either direct sales where MediWound commercializes i...
Mediwound Earnings Call Summary
Earnings Call Date:May 27, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The call presented a mix of positive strategic progress (clinical advancement for EscharEx, broad industry collaborations, strong government backing for NexoBrid via BARDA, and improved gross margin) alongside notable near-term financial and operational challenges (sharp Q1 revenue decline, higher R&D and losses, enrollment pacing issues, regulatory/ manufacturing implementation work, and reimbursement headwinds). Management reaffirmed full-year revenue guidance and outlined specific remediation steps (patient assistance, EMA actions), but near-term execution and cash consumption remain areas to watch.Positive Updates
EscharEx Phase III Progress and Expanded Clinical Program
Enrollment ongoing in global Phase III VALUE study with >30 active sites across the U.S., Europe and Israel and ~40 sites expected to be active within weeks; interim sample size reassessment and enrollment completion targeted by end of Q1 2027. Additional EscharEx development: DFU Phase II and investigator-initiated pressure ulcer study planned H2 2026, head-to-head Phase II vs collagenase planned, and required PK/human factors studies slated to start H2 2026.
Negative Updates
Significant Q1 Revenue Decline
Revenue for Q1 2026 was $1.5M vs $4.0M in Q1 2025, a decline of $2.5M or -62.5%, driven primarily by timing of BARDA-related revenue and postponed shipments due to regional conflict (company states postponed shipments have been completed).
Read all updates
Q1-2026 Updates
Positive
Negative
EscharEx Phase III Progress and Expanded Clinical Program
Enrollment ongoing in global Phase III VALUE study with >30 active sites across the U.S., Europe and Israel and ~40 sites expected to be active within weeks; interim sample size reassessment and enrollment completion targeted by end of Q1 2027. Additional EscharEx development: DFU Phase II and investigator-initiated pressure ulcer study planned H2 2026, head-to-head Phase II vs collagenase planned, and required PK/human factors studies slated to start H2 2026.
Read all positive updates
Company Guidance
MediWound reaffirmed full‑year 2026 revenue guidance of $24 million to $26 million, stating revenue will be weighted to the second half of the year driven primarily by expected government‑related procurement and development (BARDA/Vericel 10‑year contract up to $197M; ~ $138M previously received from BARDA/DOD), with BARDA‑related work expected to begin in H2 2026. Q1 results: revenue $1.5M (vs. $4.0M LY), gross profit $0.3M (21.9% margin; vs. $0.7M/18.7%), R&D $5.2M (vs. $2.9M), SG&A $3.6M (vs. $3.1M), operating loss $8.0M (vs. $5.2M), net loss $3.0M or $0.23/share (vs. $0.7M or $0.07), adjusted EBITDA loss $7.0M (vs. $4.0M); cash and equivalents $45M (vs. $54M YE2025), Q1 operating cash use $9.6M, plus $1.2M EIC grant received and $0.7M warrant exercise post‑quarter. Key program/timing notes: EscharEx VALUE enrollment shifted ~1 quarter (>30 sites active, target 40 sites within weeks; interim reassessment and enrollment completion by end Q1 2027), DFU Phase II and pressure‑ulcer IIT planned H2 2026, and NexoBrid facility modifications expected complete H2 2026 with U.S. inspection early 2027.Mediwound Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.48M | 16.96M | 20.22M | 18.69M | 26.50M | 23.76M |
| Gross Profit | 2.84M | 3.25M | 2.63M | 3.58M | 13.16M | 8.77M |
| EBITDA | -14.84M | -21.47M | -27.93M | -4.80M | -18.25M | -11.38M |
| Net Income | -26.11M | -23.88M | -30.22M | -6.72M | -19.60M | -13.55M |
Balance Sheet | ||||||
| Total Assets | 79.98M | 86.25M | 73.50M | 66.46M | 50.02M | 19.74M |
| Cash, Cash Equivalents and Short-Term Investments | 44.65M | 53.14M | 43.16M | 41.54M | 33.90M | 11.05M |
| Total Debt | 8.13M | 8.77M | 6.93M | 6.35M | 846.00K | 1.39M |
| Total Liabilities | 38.56M | 34.33M | 42.34M | 34.86M | 39.10M | 24.33M |
| Stockholders Equity | 41.42M | 43.63M | 31.15M | 31.59M | 10.91M | -4.58M |
Cash Flow | ||||||
| Free Cash Flow | -24.32M | -20.04M | -19.90M | -16.93M | -12.44M | -9.40M |
| Operating Cash Flow | -17.86M | -14.53M | -13.62M | -10.46M | -11.88M | -8.92M |
| Investing Cash Flow | 1.49M | -19.54M | -8.40M | -34.32M | -481.00K | 3.55M |
| Financing Cash Flow | 30.48M | 29.62M | 19.39M | 22.92M | 35.76M | -1.05M |
Mediwound Technical Analysis
Negative
16.40
Price Trends
16.19
Negative
16.72
Negative
17.36
Negative
Market Momentum
-0.67
Positive
38.65
Neutral
38.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Negative. The current price of 16.4 is above the 20-day moving average (MA) of 15.02, above the 50-day MA of 16.19, and below the 200-day MA of 17.36, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 38.65 is Neutral, neither overbought nor oversold. The STOCH value of 38.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDWD.
Mediwound Risk Analysis
Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mediwound Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $275.56M | ― | -96.80% | ― | ― | -1.48% | |
52 Neutral | $685.15M | -9.67 | -33.07% | ― | ― | -20.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $43.84M | -1.71 | 241.39% | ― | ― | 38.95% | |
47 Neutral | $316.61M | -4.85 | -152.10% | ― | 54.64% | -250.94% | |
43 Neutral | $182.67M | -7.01 | -67.22% | ― | -24.64% | -8.25% |
* Healthcare Sector Average
MDWD
Mediwound
14.22
-6.27
-30.60%
LCTX
Lineage Therap
1.27
0.41
46.99%
ELDN
Eledon Pharmaceuticals
3.57
0.77
27.50%
DSGN
Design Therapeutics
10.97
7.10
183.46%
TVGN
Tevogen Bio Holdings
10.47
-53.03
-83.51%
Mediwound Corporate Events
MediWound Q1 2026 Results Highlight EscharEx Trial Progress and BARDA Boost for NexoBrid
May 27, 2026
On May 27, 2026, MediWound reported first-quarter 2026 revenue of $1.5 million, down from $4.0 million a year earlier, mainly due to BARDA revenue timing and conflict-related shipment delays, while reaffirming full-year revenue guidance of $24 mil...
MediWound Shareholders Back Board, Auditor and CEO Bonus at 2026 Annual Meeting
May 6, 2026
On May 6, 2026, MediWound Ltd. held its 2026 annual general meeting of shareholders in Israel, where investors re-elected five incumbent directors to the board with overwhelming majorities, ensuring continuity in the company’s governance and...
MediWound Highlights Vericel’s $197 Million BARDA Contract for NexoBrid
Apr 2, 2026
On April 2, 2026, MediWound reported that its North American partner Vericel secured a ten-year BARDA contract, effective April 1, 2026, valued at up to $197 million for NexoBrid. The base $35 million portion includes about $10 million over the ne...
MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus
Mar 30, 2026
On March 30, 2026, MediWound filed a Form 6-K announcing it had published proxy materials and notice for its 2026 annual general meeting of shareholders, to be held on May 6, 2026 in New York. The meeting will cover the re-election of five directo...
MediWound Posts 2025 Loss but Strengthens Cash and Advances EscharEx, NexoBrid Capacity
Mar 5, 2026
On March 5, 2026, MediWound reported fourth‑quarter and full‑year 2025 results, highlighting $17 million in 2025 revenue, a net loss of $23.9 million, and a year‑end cash balance of $53.6 million strengthened by a $30 million dir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.